ストックスクリーナーアプリを入手
456.95
1.39%
6.27
アフターアワーズ：
456.95
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Price Action & Expert Curated Trade Ideas - newser.com
Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morgan Stanley | ALNY Stock News - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Forecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Alnylam Pharmaceuticals Inc a good long term investmentStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Is Alnylam Pharmaceuticals Inc DUL a good long term investmentGlobal Trade Effects & Build Wealth Brick by Brick With Us - earlytimes.in
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growth2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Is Alnylam Pharmaceuticals Inc. stock ready for breakout2025 Trade Ideas & High Win Rate Trade Tips - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After ZENITH Phase 3 Trial Launch and HELIOS-B Data Reveal - simplywall.st
Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Set To Breakeven - Yahoo Finance
AMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Kevin Joseph Fitzgerald Sells 2,441 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $4,034,094.20 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,727,283.05 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,405 Shares - MarketBeat
Alnylam Pharma Secures $500M Credit Agreement - TipRanks
Alnylam Pharmaceuticals says on Sept 30, entered into credit agreement with Bank of AmericaSEC filing - MarketScreener
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Does Alnylam Pharmaceuticals Inc. show high probability of rebound2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
8,322 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Lbp Am Sa - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam (ALNY) Reports 238% Growth in Amvuttra Since February Launch, RBC Raises Price Target - Yahoo Finance
Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots - Bloomberg.com
Alnylam Pharmaceuticals (ALNY) Pulls Ad After FDA Warning - GuruFocus
Alnylam yanks Amvuttra TV ad following FDA letterreport - Seeking Alpha
Cambridge-based Alnylam Pharmaceuticals pulls TV ad after Trump crackdown on drug industry spots - The Boston Globe
Alnylam pulls heart drug TV ad amid FDA crackdown - Investing.com
Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5% - MSN
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - BioSpace
1.07%
4.36%
大文字化:
|
ボリューム (24 時間):